{"id":50338,"date":"2025-12-10T21:31:25","date_gmt":"2025-12-10T13:31:25","guid":{"rendered":"https:\/\/flcube.com\/?p=50338"},"modified":"2025-12-10T21:31:26","modified_gmt":"2025-12-10T13:31:26","slug":"cygenta-horicin-msc-partnership-accelerates-cell-therapy-development","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=50338","title":{"rendered":"Cygenta Horicin MSC Partnership Accelerates Cell Therapy Development"},"content":{"rendered":"\n<p><strong>Beijing Cygenta Biotech Co., Ltd.<\/strong> and <strong>Beijing Horicin Biotechnology Co., Ltd.<\/strong> announced a strategic partnership focused on <strong>Mesenchymal Stromal Cell (MSC) therapeutic products<\/strong>, aiming to accelerate clinical translation of regenerative medicine. Cygenta will provide comprehensive <strong>CDMO services<\/strong> from pharmaceutical development to IND application support.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-partnership-framework-amp-strategic-focus\">Partnership Framework &amp; Strategic Focus<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Companies<\/strong><\/td><td>Cygenta Biotech + Horicin Biotechnology<\/td><\/tr><tr><td><strong>Technology<\/strong><\/td><td>Mesenchymal Stromal Cell (MSC) therapeutic products<\/td><\/tr><tr><td><strong>Collaboration Model<\/strong><\/td><td>Cygenta provides comprehensive CDMO services<\/td><\/tr><tr><td><strong>Scope<\/strong><\/td><td>Full chain from pharmaceutical services to IND application support<\/td><\/tr><tr><td><strong>Strategic Goal<\/strong><\/td><td>Accelerate efficient clinical translation of regenerative medicine products<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-horicin-biotechnology-profile\">Horicin Biotechnology Profile<\/h2>\n\n\n\n<p><strong>Founded<\/strong>: 1999<br><strong>Status<\/strong>: National High-Tech Enterprise<br><strong>Core Business<\/strong>: New drug R&amp;D and technical services<\/p>\n\n\n\n<p><strong>Therapeutic Focus Areas:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Anti-cancer targeted drugs<\/li>\n\n\n\n<li>Central nervous system drugs<\/li>\n\n\n\n<li>Cardiovascular and cerebrovascular drugs<\/li>\n\n\n\n<li>Anti-infective drugs<\/li>\n\n\n\n<li>Gynecological drugs<\/li>\n\n\n\n<li>Digestive system drugs<\/li>\n\n\n\n<li>Topical medicines<\/li>\n<\/ul>\n\n\n\n<p><strong>R&amp;D Capabilities<\/strong>: Covers chemical, traditional Chinese, and biological medicines<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-cygenta-biotech-profile\">Cygenta Biotech Profile<\/h2>\n\n\n\n<p><strong>Headquarters<\/strong>: Beijing<br><strong>Facilities<\/strong>: &gt;8,000 square meters of CGT (Cell and Gene Therapy) cGMP compliant facilities<br><strong>Standards<\/strong>: Meet FDA, EMA, and NMPA regulatory requirements<br><strong>Services<\/strong>: Manufacturing for plasmid, viral vector, and cell products from research grade to commercialization grade<\/p>\n\n\n\n<p><strong>Client Base<\/strong>: Gene and cell therapy companies requiring integrated manufacturing solutions<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale-amp-market-impact\">Strategic Rationale &amp; Market Impact<\/h2>\n\n\n\n<p><strong>Synergy Creation:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Horicin&#8217;s Pipeline<\/strong>: Deep expertise in multiple therapeutic areas with MSC application potential<\/li>\n\n\n\n<li><strong>Cygenta&#8217;s Infrastructure<\/strong>: State-of-the-art manufacturing capacity reduces development timelines<\/li>\n\n\n\n<li><strong>Full Integration<\/strong>: End-to-end service eliminates gaps between R&amp;D and clinical manufacturing<\/li>\n<\/ul>\n\n\n\n<p><strong>Market Context:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>MSC Market<\/strong>: Global MSC therapy market projected <strong>$15 billion<\/strong> by 2030, growing at <strong>22% CAGR<\/strong><\/li>\n\n\n\n<li><strong>China Advantage<\/strong>: Regulatory support for cell therapy innovation accelerates clinical translation<\/li>\n\n\n\n<li><strong>CDMO Demand<\/strong>: Domestic biotech companies increasingly outsourcing manufacturing to specialized providers<\/li>\n<\/ul>\n\n\n\n<p><strong>Competitive Positioning:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First Mover<\/strong>: Among few China-based CDMOs offering complete MSC therapy services<\/li>\n\n\n\n<li><strong>Quality Standards<\/strong>: Multi-regulatory compliance enables global clinical development pathways<\/li>\n\n\n\n<li><strong>Scalability<\/strong>: 8,000+ sqm facility supports multiple parallel client programs<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the partnership&#8217;s execution, technology development timelines, and commercial prospects. Actual results may differ due to regulatory processes, technology transfer challenges, and competitive dynamics in the cell therapy CDMO market.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Beijing Cygenta Biotech Co., Ltd. and Beijing Horicin Biotechnology Co., Ltd. announced a strategic partnership&#8230;<\/p>\n","protected":false},"author":1,"featured_media":50347,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[77,3026,4495],"class_list":["post-50338","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-cell-therapy","tag-cygenta","tag-horicin-biotechnology"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Cygenta Horicin MSC Partnership Accelerates Cell Therapy Development - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Beijing Cygenta Biotech Co., Ltd. and Beijing Horicin Biotechnology Co., Ltd. announced a strategic partnership focused on Mesenchymal Stromal Cell (MSC) therapeutic products, aiming to accelerate clinical translation of regenerative medicine. Cygenta will provide comprehensive CDMO services from pharmaceutical development to IND application support.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=50338\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cygenta Horicin MSC Partnership Accelerates Cell Therapy Development\" \/>\n<meta property=\"og:description\" content=\"Beijing Cygenta Biotech Co., Ltd. and Beijing Horicin Biotechnology Co., Ltd. announced a strategic partnership focused on Mesenchymal Stromal Cell (MSC) therapeutic products, aiming to accelerate clinical translation of regenerative medicine. Cygenta will provide comprehensive CDMO services from pharmaceutical development to IND application support.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=50338\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-10T13:31:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-10T13:31:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1002.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50338#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50338\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Cygenta Horicin MSC Partnership Accelerates Cell Therapy Development\",\"datePublished\":\"2025-12-10T13:31:25+00:00\",\"dateModified\":\"2025-12-10T13:31:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50338\"},\"wordCount\":354,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50338#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1002.webp\",\"keywords\":[\"Cell-therapy\",\"Cygenta\",\"Horicin Biotechnology\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=50338#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50338\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=50338\",\"name\":\"Cygenta Horicin MSC Partnership Accelerates Cell Therapy Development - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50338#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50338#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1002.webp\",\"datePublished\":\"2025-12-10T13:31:25+00:00\",\"dateModified\":\"2025-12-10T13:31:26+00:00\",\"description\":\"Beijing Cygenta Biotech Co., Ltd. and Beijing Horicin Biotechnology Co., Ltd. announced a strategic partnership focused on Mesenchymal Stromal Cell (MSC) therapeutic products, aiming to accelerate clinical translation of regenerative medicine. Cygenta will provide comprehensive CDMO services from pharmaceutical development to IND application support.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50338#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=50338\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50338#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1002.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1002.webp\",\"width\":1080,\"height\":608,\"caption\":\"Cygenta Horicin MSC Partnership Accelerates Cell Therapy Development\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50338#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cygenta Horicin MSC Partnership Accelerates Cell Therapy Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Cygenta Horicin MSC Partnership Accelerates Cell Therapy Development - Insight, China&#039;s Pharmaceutical Industry","description":"Beijing Cygenta Biotech Co., Ltd. and Beijing Horicin Biotechnology Co., Ltd. announced a strategic partnership focused on Mesenchymal Stromal Cell (MSC) therapeutic products, aiming to accelerate clinical translation of regenerative medicine. Cygenta will provide comprehensive CDMO services from pharmaceutical development to IND application support.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=50338","og_locale":"en_US","og_type":"article","og_title":"Cygenta Horicin MSC Partnership Accelerates Cell Therapy Development","og_description":"Beijing Cygenta Biotech Co., Ltd. and Beijing Horicin Biotechnology Co., Ltd. announced a strategic partnership focused on Mesenchymal Stromal Cell (MSC) therapeutic products, aiming to accelerate clinical translation of regenerative medicine. Cygenta will provide comprehensive CDMO services from pharmaceutical development to IND application support.","og_url":"https:\/\/flcube.com\/?p=50338","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-10T13:31:25+00:00","article_modified_time":"2025-12-10T13:31:26+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1002.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=50338#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=50338"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Cygenta Horicin MSC Partnership Accelerates Cell Therapy Development","datePublished":"2025-12-10T13:31:25+00:00","dateModified":"2025-12-10T13:31:26+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=50338"},"wordCount":354,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=50338#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1002.webp","keywords":["Cell-therapy","Cygenta","Horicin Biotechnology"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=50338#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=50338","url":"https:\/\/flcube.com\/?p=50338","name":"Cygenta Horicin MSC Partnership Accelerates Cell Therapy Development - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=50338#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=50338#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1002.webp","datePublished":"2025-12-10T13:31:25+00:00","dateModified":"2025-12-10T13:31:26+00:00","description":"Beijing Cygenta Biotech Co., Ltd. and Beijing Horicin Biotechnology Co., Ltd. announced a strategic partnership focused on Mesenchymal Stromal Cell (MSC) therapeutic products, aiming to accelerate clinical translation of regenerative medicine. Cygenta will provide comprehensive CDMO services from pharmaceutical development to IND application support.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=50338#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=50338"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=50338#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1002.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1002.webp","width":1080,"height":608,"caption":"Cygenta Horicin MSC Partnership Accelerates Cell Therapy Development"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=50338#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Cygenta Horicin MSC Partnership Accelerates Cell Therapy Development"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1002.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50338","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=50338"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50338\/revisions"}],"predecessor-version":[{"id":50348,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50338\/revisions\/50348"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/50347"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=50338"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=50338"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=50338"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}